摘要
目的:评价一种新型仿生材料用于硬脑膜缺损修复的安全性及有效性。方法:采用增材制造技术制备的聚乳酸新型仿生材料,分别开展了体外和体内研究,研究材料的微观结构、细胞增殖活性、力学特性,以及原位植入硬脑膜缺损后,与周边组织相容性和缺损硬脑膜修复情况等。结果:新型仿生材料微观结构为三维网络结构,对细胞增值活性无影响,其拉伸强度和断裂伸长率均明显高于对照品EthisorbTM。动物实验研究显示材料组织相容性良好,可实现硬脑膜缺损修复。结论:新型仿生材料具有较好的力学性能,组织相容性良好,可诱导周边组织细胞爬行到支架,诱导新生毛细血管生成促进新生组织形成,可作为硬膜缺损修复的新材料,实现硬脑膜再生修复。
Objective: To evaluate the safety and efficacy of the novel biomimetic material in dura mater defect repair. Methods: The novel biomimetic material were fabricated by the additive manufacturing technology, and the in-vitro and vitro studies were performed for the novel biomimetic material, to study the microstructure, cell proliferation activity, mechanical properties of the materials, as well as after the novel biomimetic material were implanted in situ, the compatibility with the sur-rounding tissue and repair effect of the defect dura mater and so on. Results: The microstructure of the new biomimetic material was three-dimensional network structure, which had no effect on the proliferation activity of cells. The tensile strength and elongation at break of the novel biomimetic material were significantly higher than that of the control group EthisorbTM. Animal study showed that the novel biomimetic material has good biocompatibility with the tissue and can repair defect dura mater. Conclusion: The novel biomimetic material has good mechanical properties and good biocompatibility, and it can induce the surrounding tissue cells to migrate to the scaffold, and in-duce the new capillary angiogenesis to promote the new tissue formation. Thus, it can be used as a new material for dura defect repair to achieve dura mater.
出处
《临床医学进展》
2022年第12期11631-11642,共12页
Advances in Clinical Medicine